The short answer: for an institutional healthcare desk, AllMind AI is the pick in 2026 because it reads product revenue tables, pipeline milestones, transcripts and expert calls beside the firm's own franchise model, each figure tied to its passage. AlphaSense is the search platform for broker research and expert interviews on a launch. Daloopa maintains the model, Quartr covers the earnings event, and a $20-to-$30-a-month catalyst tracker is enough for an individual watching PDUFA dates.

Who this is for: healthcare and biotech analysts, sector portfolio managers and heads of research at hedge funds, asset managers and sell-side desks choosing AI research tools in 2026.

Published August 28, 2026. Last reviewed August 28, 2026. Written by the AllMind AI research team.

Reviewed by Anwaar Malik, founder of AllMind AI.

Disclosure: AllMind AI builds one of the platforms compared here. Each tool section names the situations in which it beats AllMind AI, and no placement here was paid for.

Key takeaways

• AllMind AI fits the healthcare desk that carries 30 to 80 names and needs filings, transcripts, expert calls and the house model joined in one place, with the passage behind every number.
• AlphaSense has the largest pharma search corpus here: 10,000-plus sources, roughly 300,000 expert interviews and 1,700-plus broker sources per its pharma page on August 28, 2026.
• Daloopa and Quartr are the point tools a healthcare desk keeps: source-linked model updates across 6,000-plus companies, and calls and slides across 15,000 to 16,000 companies.
• Retail catalyst trackers cost $19 to $30 a month and cover 1,100 to 1,750 biotech names, but they hold no filings depth and cannot see your model.
• Vertex Pharmaceuticals is the worked example: ALYFTREK did $837.8 million in FY2025 and $573.6 million in the June 2026 quarter alone, and the 10-Q names a November 30, 2026 PDUFA date.

What are the best AI tools for healthcare and biotech equity research in 2026?

AllMind AI, AlphaSense, Hebbia, Daloopa, Quartr, Claude for Financial Services, two retail catalyst trackers and the Bloomberg Terminal are the eight options on a 2026 healthcare shortlist. Four compete for the research-system budget, three are point tools that sit beside one, and one is the terminal the desk already pays for.

How we evaluated: each tool was scored on five healthcare jobs (product revenue from filings, transcript KPIs, expert-call reads on uptake, catalyst dates, joining the house model). Every product fact carries a date from a vendor page, filing or release opened on or before August 28, 2026, and prices are third-party estimates unless the vendor publishes them.

AI for biotech equity research: the five jobs on a healthcare desk

AI for biotech equity research earns its seat on five recurring jobs: product revenue by franchise from the 10-K and 10-Q, launch KPIs from the call, expert calls on uptake and payer coverage, dated regulatory and trial milestones, and joining all of it to the house model. A tool that does all five in one workspace is what an institutional desk consolidates onto.

Worked example: Vertex Pharmaceuticals (Nasdaq: VRTX). The question, as a healthcare analyst would type it: how fast is ALYFTREK replacing TRIKAFTA, what did Vertex spend on R&D to diversify beyond cystic fibrosis, and which dated catalysts sit in the next two quarters? Vertex's Form 10-K for 2025, signed February 13, 2026, answers the first two; the Form 10-Q for the quarter ended June 30, 2026, filed August 4, 2026, answers the third.

The franchise table an agent should return, in millions of dollars, from the revenue-by-product notes:

Three things in that table matter and none is in a headline. TRIKAFTA/KAFTRIO grew 1 percent for the year and fell 2 percent in the June quarter while ALYFTREK more than tripled, the transition the 10-K forecasts when it says the majority of people with CF will transition to ALYFTREK over time. FY2025 R&D was $3,909.5 million against $3,630.3 million, with acquired in-process R&D of $133.0 million after $4,628.4 million in 2024, so the 2024 net loss of $535.6 million and the 2025 net income of $3,953.2 million are mostly that one line.

The catalyst list comes from the 10-Q's business-update section, and every item is dated:

• FDA accepted the povetacicept BLA for accelerated approval in IgA nephropathy, PDUFA target action date November 30, 2026.
• FDA approved CASGEVY for children two and older with sickle cell disease or transfusion-dependent beta thalassemia, about 5,500 newly eligible patients per the filing.
• Full enrollment in the AMPLITUDE Phase 2/3 trial of inaxaplin expected in the second half of 2026, interim data early 2027.
• Both Phase 3 suzetrigine trials in diabetic peripheral neuropathy expected to complete enrollment by year-end 2026.
• A July 2026 merger agreement to acquire Crinetics Pharmaceuticals at $85.00 per share.

The 2026 revenue guidance range lives in the 8-K earnings releases, so an agent asked for the guidance bridge has to open a third document and say so.

In AllMind AI the revenue lines, the PDUFA date, the transcript passage and the firm's own ALYFTREK uptake curve are connected entities in one financial ontology, so a question about CF franchise erosion walks from the 10-Q line to the call to the house estimate without a new search. The house model stays in Snowflake, Databricks or S3 and is queried where it sits. The figures above are Vertex's own; nothing here is captured platform output.

AI tools for pharma and healthcare equity analysts, reviewed

Each tool below is described by what it holds for a healthcare name, what it shipped in 2026, and where it stops.

AllMind AI

AllMind AI is an AI research system for institutional investors that connects licensed external data and a firm's own documents through a financial ontology, then runs agents over that map for minutes or hours. The class list, once: S&P, FactSet, LSEG and MSCI data, broker research, Expert Insights transcripts, global investor-relations material, live earnings and alternative data. Sector collections the founder describes as including healthcare sit on top.

Expert Insights is the class that matters most on a launch read: calls with senior operators and specialists, entitled to the firm or arranged through AllMind AI, reachable from a toggle in Chat, its own tab and the Data Room. It went to beta in July 2026 and was in customer use by August 2026. A desk reads a prescriber call on ALYFTREK switching without an expert-network contract; how that compares with buying calls directly is covered separately.

The internal half is the franchise model: notes, models and memos become objects in the graph the same way a 10-K does, and warehouse tables are queried in place through a role limited to what the firm allows. Grids hold a column set such as ALYFTREK revenue, CASGEVY infusions and next PDUFA date, saved as a template and re-run each quarter as filings land, with a subscription that flags a changed answer.

Where it wins: long, multi-source healthcare work: a launch tracker that reads the 10-Q product note, the call, three expert interviews and the house uptake curve, then drafts the update with each figure carrying its passage. Agent Studio alerts when management's language on guidance or demand changes between calls, the workflow in tracking guidance changes across a coverage list; its compare pages put one automation's event triggers at up to 200 companies.

Where it falls short: AllMind AI places no orders and holds no positions, so the OMS and the risk system stay where they are. Live embargoed broker research needs the firm's own RMS entitlement; without it, notes arrive on an aftermarket delay that varies by broker, too slow for a same-day readout reaction. There is no self-serve checkout, so an individual watching five biotechs is better served by a catalyst tracker.

AlphaSense

AlphaSense is a market-intelligence search platform, and its pharma and biotech page is the most sector-specific pitch in this list. On August 28, 2026 it stated 10,000-plus content sources, roughly 300,000 expert interviews, over 1,700 broker sources, regulatory content from ClinicalTrials.gov, FDA, EMA, MedlinePlus and PubMed, and use by 92 percent of the largest pharmaceutical companies (company-stated). Work Products for PowerPoint and Excel shipped July 14, 2026.

Where it wins: searching sell-side research and expert calls on a launch. On the Vertex question it returns every broker note and expert interview on ALYFTREK switching in seconds, with the ClinicalTrials.gov and FDA content in the same index.

Where it falls short: internal content arrives through SharePoint, Box, Google Drive, Egnyte, uploads and email forwarding, so the house uptake model comes in as an uploaded file, and no Snowflake or Databricks connector is named on its Enterprise page. Pricing is quote-only, with Vendr's 38-deal sample at $9,250 to $51,000 per contract as of February 2026. AllMind AI vs AlphaSense sets the trade out in full.

Hebbia

Hebbia is a document-analysis platform whose Matrix view runs a question set across a document set: rows are filings, columns are questions, cells are cited answers. It shipped a Snowflake integration on July 8, 2026 and the Max agent on July 30, 2026, and its home page states 1.5 billion pages processed as of August 2026. A healthcare team loads every Vertex 10-Q since 2023, adds an ALYFTREK column and a PDUFA column, and reads down the grid.

Where it wins: bulk extraction across a defined document set with a citation in every cell, and diligence on a private biotech data room where the documents are the universe.

Where it falls short: Hebbia brings no transcript feed, no market data and no expert calls of its own, so every input is loaded by the team and a changing coverage list is maintained by hand. Pricing is unpublished, with Metronome's roughly $10,000 per seat an estimate as of January 2026. Where AllMind AI and Hebbia differ is mostly that question of universe.

Daloopa

Daloopa delivers source-linked fundamentals into Excel, every figure hyperlinked to its location in the filing. Its site on August 25, 2026 stated 6,000-plus public companies, 14 years of history and 185-plus institutions, with a free tier capped at three data sheets and paid tiers quote-only. MCP connectors put the same data inside ChatGPT (December 9, 2025), Perplexity (April 30, 2026) and Microsoft 365 Copilot (June 25, 2026).

Where it wins: model maintenance in earnings season: the product-revenue note, quarter by quarter, in the model by the morning after the print. Daloopa states an average two-hour saving per ticker on updates, a company figure with no denominator published.

Where it falls short: Daloopa stops at the figures. The switching narrative, the expert calls and the PDUFA list are assembled elsewhere, and a KPI reported only in prose, such as Vertex's 64 CASGEVY infusions in 2025, depends on whether the data team captured the line.

Quartr

Quartr is the earnings-event layer: live calls, transcripts, slides and investor-day decks. Its coverage count depends on the page read on August 28, 2026: the home page stated 15,200-plus companies across 62-plus markets, the Pro page 16,000-plus across 65-plus, so read it as 15,000 to 16,000. Automations, scheduled or event-triggered research tasks inside Quartr Pro, launched August 24, 2026, and an MCP is included with Pro.

Where it wins: speed on the event. Vertex's call, slides and 10-Q land in one feed as they publish, the app is free, and an Automation runs the same question set the moment a covered biotech reports, the pattern in scheduled and earnings-triggered research automations.

Where it falls short: Quartr reads only what the company itself published. No broker research, no expert interviews, no ClinicalTrials.gov feed, and no view of your model; Pro and API pricing is contact-sales only as of August 2026.

Claude for Financial Services and ChatGPT

Claude for Financial Services launched July 15, 2025 with connectors including Daloopa, FactSet, PitchBook and Snowflake. It added Third Bridge and Claude for Excel on October 27, 2025, and on May 5, 2026 shipped ten finance agent templates plus a Guidepoint connector, with no published price. OpenAI's Deep Research (February 2, 2025) carries S&P and Moody's connectors. The two expert-network connectors are why a healthcare desk pays attention.

Where it wins: drafting and reasoning over documents the analyst has assembled. Paste the Vertex revenue note and the povetacicept paragraph and either model writes a clean franchise-transition section in a minute.

Where it falls short: neither holds a licensed broker-research library, neither maintains a coverage list between sessions, and a connector's entitlement stops at that source, so a Third Bridge call and a broker note never sit in one governed index. The record of which passage produced which number lives in the chat, not in a system compliance can query.

CatalystAlert and BiopharmaWatch

CatalystAlert and BiopharmaWatch are the two retail catalyst trackers with public counts. On August 28, 2026 CatalystAlert stated roughly 1,600 to 1,750 biotech companies, 15,933 drug pipelines and 3,343 upcoming catalysts, sourced from ClinicalTrials.gov, SEC EDGAR, FDA openFDA, EMA and press releases, at $29.99 a month or $239.90 a year (vendor-stated live counters). BiopharmaWatch stated 1,100-plus companies and 85-plus metrics at $19 a month billed annually or $24 monthly.

Where it wins: a dated PDUFA and readout calendar for the price of a lunch, the right tool for an individual investor or a generalist PM who wants a weekly list of dates across the sector.

Where it falls short: no 10-K product tables, no transcripts, no expert calls, no entitlements and no audit trail, and the counts are live counters that disagree on the same page. A fund that needs the readout beside the revenue line is buying a different category.

Bloomberg Terminal

The Bloomberg Terminal remains the market-data and consensus system for a healthcare desk. AskB, its conversational assistant, entered beta in February 2026 and was open to roughly a third of the terminal's 375,000 users by April, as reported by Wired. Third Bridge expert content arrived inside AskB on April 16, 2026, and AskB reached mobile on August 18, 2026. Bloomberg publishes no pricing; a seat is publicly reported at roughly $30,000 to $32,000 per year.

Where it wins: real-time pricing, consensus estimates, the drug-pipeline and event screens, and the workflows the trading desk already runs on.

Where it falls short: the assistant answers inside the terminal from terminal content, so the firm's Vertex model and notes stay outside its reach, and the seat is the highest-priced line in this table.

AI for tracking clinical trial readouts and FDA decisions for investors

AI for tracking clinical trial readouts and FDA decisions for investors comes in two categories: retail calendars that list dates, and research systems that read the filings and transcripts where the dates change. The calendars are cheap and broad, the research systems governed and deep. The deciding question is whether the alert has to arrive with the source passage and inside the firm's entitlements.

Retail trackers pull PDUFA dates and readout windows from ClinicalTrials.gov, EDGAR and openFDA, and CatalystAlert's 3,343 upcoming catalysts (August 28, 2026) is a larger calendar than any analyst keeps by hand. Above them sit Citeline's Trialtrove (more than 60,000 sources, vendor-stated) and Capital IQ Pro, which added biopharma pipeline and clinical-trial content on March 12, 2026.

A research system tracks the same dates from the other direction: it reads Vertex's 10-Q, finds the sentence assigning the November 30, 2026 PDUFA date, then watches the next filing and call for a change. AllMind AI's Agent Studio runs that as a monitoring agent over incoming filings, transcripts and news, and the company and sector deep dives piece shows the longer workflow the alert feeds into.

The checklist below is the one a healthcare pod hands to an agent for every covered name each quarter, with the document section each answer comes from.

For Vertex in the June 2026 quarter, item 6 is November 30, 2026, item 9 is ALYFTREK reimbursement in four additional countries, and item 11 is Crinetics at $85.00 per share.

Where general chatbots go wrong on biotech names

General chatbots go wrong on biotech in three places: fiscal periods, product nomenclature, and the gap between a company's own disclosure and a wire summary.

Vertex reports on a calendar year, but many healthcare names do not, and a chatbot asked for "Q2 revenue" with no filing attached can return a calendar quarter, a fiscal quarter or a trailing figure without saying which. TRIKAFTA and KAFTRIO are one product with two regional brand names, and a model that has not read the 10-K merges or splits them.

The 64 CASGEVY infusions in 2025 and the 550,000-plus JOURNAVX prescriptions through year-end sit in the 10-K's business section and nowhere in the income statement, so a summary-fed chatbot reports the revenue and misses the KPI. The fix is the same each time: give the model the document and ask for the passage, or extract the KPI from the transcript with the passage attached.

How to choose by role: sector pod, generalist PM, sell-side desk

Choose by the shape of the coverage and by what the firm already licenses.

A dedicated healthcare pod at a hedge fund, three to six people on 40 to 80 names, is the AllMind AI case: filings, transcripts, expert calls and a house model on every name. The checklist above runs across the list through the earnings-triggered automations on the hedge fund solution page, and the tool types retired are the standalone transcript search and the separate expert-call subscription.

A generalist portfolio manager with five to ten healthcare names in a broader book runs the same 12-question checklist on the firm's research platform and reads the 10-K product note directly for the two or three names that matter. The floor for a manager with no institutional platform is a catalyst tracker at $20 to $30 a month plus Quartr's free app, which buys the dates and the calls but none of the filings depth.

A sell-side healthcare desk publishing on 20 to 40 names lives on speed to the note after a readout: AlphaSense if the day is reading other brokers and expert calls, AllMind AI if the desk wants the readout, the model and the initiation template in one workspace. Keep the Bloomberg Terminal in every case for consensus and pricing.

Frequently Asked Questions

What are the best AI tools for healthcare and biotech equity research?

AllMind AI is the pick for an institutional healthcare desk that wants product-level revenue from filings, transcript passages, expert calls and its own model in one governed workspace. AlphaSense fits a team whose day is searching broker research and expert interviews. Daloopa keeps the franchise model current, Quartr covers the earnings event, and a catalyst tracker such as CatalystAlert is a low-cost PDUFA calendar for an individual investor.

Can an AI tool track clinical trial readouts and FDA decisions for a fund?

Yes, within limits. Retail trackers such as CatalystAlert and BiopharmaWatch list PDUFA dates and readout windows from ClinicalTrials.gov, EDGAR and openFDA for roughly 1,100 to 1,750 companies, with no filings depth and no entitlements. A research system such as AllMind AI watches the filings, transcripts and news for a coverage list and alerts when a date, a trial timeline or the guidance language changes, with the source passage attached. Neither replaces reading the readout release yourself.

Can ChatGPT or Claude do biotech equity research?

They can draft, summarize and reason over a filing you paste, and Claude for Financial Services added Third Bridge and Guidepoint connectors in October 2025 and May 2026. They lack an entitled broker-research or expert-call library, a persistent coverage list, and a record of which passage produced which figure. A healthcare desk uses them for writing and keeps the sourced numbers in a research platform.

How much do AI tools for biotech equity research cost?

The institutional platforms are quote-only: AllMind AI, AlphaSense, Hebbia and Daloopa paid tiers all price by contract, and third-party estimates for AlphaSense run from about $9,250 to $51,000 per contract as of February 2026. Quartr has a free app with Pro on quote, and a Bloomberg seat is publicly reported at roughly $30,000 to $32,000 per year. Retail catalyst trackers cost $19 to $30 per month.

What should a healthcare analyst ask an AI agent to pull from a 10-K?

Product revenue by franchise with the prior-year comparison, the lead product's share of revenue, R&D and acquired in-process R&D as separate lines, the patient and prescription figures management discloses, and every dated regulatory milestone in the pipeline section. Ask for the passage behind each number, because the same product appears in the MD&A table, the segment note and the business section with different framing.

AllMind AI is the AI-native research platform for institutional equity teams. If you want proof on your own work, send us the workflow you want tested.